Name (Synonyms) | Correlation | |
---|---|---|
drug2018 | PB1046 Wiki | 0.71 |
drug2278 | Pulmonary Vascular Permeability Index Wiki | 0.71 |
drug1609 | Low Dose (10 mg) Control Wiki | 0.71 |
drug323 | Açaí palm berry extract - natural product Wiki | 0.71 |
drug1061 | Extravascular Lung Water Index Wiki | 0.71 |
drug313 | Azithromycin Wiki | 0.12 |
drug1284 | Hydroxychloroquine Wiki | 0.07 |
drug2122 | Placebo Wiki | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
D011654 | Pulmonary Edema NIH | 1.00 |
D000075902 | Clinical Deterioration NIH | 0.50 |
D011665 | Pulmonary Valve Insufficiency NIH | 0.27 |
D006333 | Heart Failure NIH | 0.24 |
D007249 | Inflammation NIH | 0.14 |
D055371 | Acute Lung Injury NIH | 0.13 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.13 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.12 |
D013577 | Syndrome NIH | 0.07 |
D011014 | Pneumonia NIH | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0010444 | Pulmonary insufficiency HPO | 0.27 |
HP:0001635 | Congestive heart failure HPO | 0.24 |
HP:0002090 | Pneumonia HPO | 0.04 |
There are 2 clinical trials
This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of PB1046 by improving the clinical outcomes and increasing days alive and free of respiratory failure in hospitalized COVID-19 patients at high risk for rapid clinical deterioration, acute respiratory distress syndrome (ARDS) and death. The study will enroll approximately 210 hospitalized COVID-19 patients who require urgent decision-making and treatment at approximately 20 centers in the United States.
Description: PaO2:FiO2 ratio is the ratio of partial pressure of arterial oxygen to percentage of inspired oxygen
Measure: Development of ARDS (PaO2:FiO2 ratio < 300 mm Hg) during hospitalization Time: Any time point between injection initiation and Day 28Description: Composite of: Total hospital days, Total ICU days, Total days of ventilator use, Total days of ECMO, Total days of invasive hemodynamic monitoring, Total days of mechanical circulatory support, Total days of inotropic or vasopressor therapy
Measure: Reduction in hospital resource utilization defined as a composite of:total days: in hospital, in ICU, on ventilator, on ECMO, with invasive hemodynamic monitoring, with mechanical circulatory support, and with inotropic or vasopressor therapy Time: 28 daysCovid-19 also primarily affects endothelium that line up the alveoli. The resulting hypoxemia may differ from "typical" Acute Respiratory Distress Syndrome (ARDS) due to maldistribution of perfusion related to the ventilation. Thus, pathophysiology of Covid-19 ARDS is different, which requires different interventions than typical ARDS. The investigators will assess whether extravascular lung water index and permeability of the alveolar capillary differs from typical ARDS with transpulmonary thermodilution (TPTD) technique. Extravascular Lung Water Index (EVLWI) and Pulmonary Vascular Permeability Index (PVPI) will be compared.
Description: The amount of fluid accumulated in the lung measured by transpulmonary thermodilution (ml/kg)
Measure: Extravascular Lung Water Index Time: 1 dayDescription: Integrity of the alveolocapillary barrier measured by transpulmonary thermodilution
Measure: Pulmonary vascular permeability index Time: 1 day